drugset / Trial / NCT02848183

Optimal Treatment Strategy Based on for Pediatric AML

NCT02848183

Phase 2 Unknown 350 enrolled Samsung Medical Center
NaSingle-groupTreatment

Summary

The purpose of this study is to optimize therapy according to the known risk factors and treatment response in pediatric acute myeloid leukemia (AML)

Timeline

Start
2016-01
Primary completion
2020-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule
Subject Etoposide Small molecule
Subject Idarubicin Small molecule
Subject Mitoxantrone Small molecule